Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

ClinicalTrials.gov ID: NCT00106288

Public ClinicalTrials.gov record NCT00106288. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double Blind, Comparative, Randomized Study to Evaluate the Efficacy and Safety of Micafungin (FK463) Versus Liposomal Amphotericin B (AmBisome) in the Treatment of Invasive Candidiasis and Candidemia

Study identification

NCT ID: NCT00106288
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Astellas Pharma Inc; Industry
Enrollment: 637 participants

Conditions and interventions

Conditions

Candidiasis

Interventions

Micafungin Drug
Liposomal Amphotericin B Drug

Drug

Eligibility (public fields only)

Age range: Not listed
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2002
Primary completion: Nov 30, 2005
Completion: Nov 30, 2005
Last update posted: Sep 17, 2014

2003 – 2005

United States locations

U.S. sites: 27
U.S. states: 18
U.S. cities: 22

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35294-0006	—
Not listed	Orange	California	92868	—
Not listed	Denver	Colorado	80218	—
Not listed	Washington D.C.	District of Columbia	20010-2970	—
Not listed	Jacksonville	Florida	32207	—
Not listed	Atlanta	Georgia	30322	—
Not listed	Hinsdale	Illinois	60521	—
Not listed	Maywood	Illinois	60153	—
Not listed	Kansas City	Kansas	66160	—
Not listed	Lexington	Kentucky	40536-0084	—
Not listed	Baltimore	Maryland	21201-1595	—
Not listed	Boston	Massachusetts	02115	—
Not listed	Boston	Massachusetts	02211	—
Not listed	Detroit	Michigan	48201	—
Not listed	Minneapolis	Minnesota	55455	—
Not listed	New York	New York	10021	—
Not listed	New York	New York	10029	—
Not listed	New York	New York	10032	—
Not listed	Rochester	New York	14642	—
Not listed	Valhalla	New York	10595	—
Not listed	Durham	North Carolina	27710	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Philadelphia	Pennsylvania	19107	—
Not listed	Philadelphia	Pennsylvania	19140	—
Not listed	Houston	Texas	77030	—
Not listed	San Antonio	Texas	78229-3900	—
Not listed	Provo	Utah	84604	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00106288, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 17, 2014 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00106288 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →